The Justice Department’s Antitrust Division has resumed a targeted Hart-Scott-Rodino review process, an important signal that federal merger scrutiny remains active and potentially more exacting for certain transactions. While this development is not tied to a single headline-grabbing court fight, it matters because the HSR process is the front door to U.S. merger enforcement: changes in how the government screens deals can directly affect closing timelines, regulatory strategy, and overall transaction risk.

The announcement from the U.S. Department of Justice Antitrust Division suggests that parties should expect renewed attention to selected reportable deals during the premerger review stage.

One of the most closely watched healthcare merger disputes is still the Justice Department’s challenge to UnitedHealth Group’s proposed acquisition of Amedisys — and, just as importantly, the government’s willingness to resolve that challenge through a divestiture package rather than insisting on an all-or-nothing court fight.

The proposed settlement, reached with the U.S. Department of Justice and a coalition of state attorneys general from Maryland, Illinois, New Jersey, and New York, would require substantial asset sales to address competitive concerns tied to home health and hospice markets.